Karyopharm Therapeutics Inc.
KPTI
$8.38
-$0.17-1.99%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 34.08M | 44.04M | 37.93M | 30.02M | 30.54M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 34.08M | 44.04M | 37.93M | 30.02M | 30.54M |
| Cost of Revenue | 29.15M | 32.66M | 33.84M | 35.92M | 34.63M |
| Gross Profit | 4.93M | 11.39M | 4.09M | -5.90M | -4.09M |
| SG&A Expenses | 22.77M | 26.61M | 28.48M | 27.35M | 27.19M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 51.92M | 59.26M | 62.32M | 63.27M | 61.82M |
| Operating Income | -17.84M | -15.22M | -24.39M | -33.26M | -31.28M |
| Income Before Tax | -102.27M | -33.09M | -37.21M | -23.43M | -30.89M |
| Income Tax Expenses | -67.00K | 34.00K | 40.00K | 36.00K | -109.00K |
| Earnings from Continuing Operations | -102.20M | -33.13M | -37.25M | -23.46M | -30.78M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -102.20M | -33.13M | -37.25M | -23.46M | -30.78M |
| EBIT | -17.84M | -15.22M | -24.39M | -33.26M | -31.28M |
| EBITDA | -17.83M | -15.10M | -24.31M | -33.18M | -31.20M |
| EPS Basic | -5.71 | -3.82 | -4.32 | -2.77 | -3.67 |
| Normalized Basic EPS | -1.39 | -2.39 | -2.70 | -1.73 | -2.30 |
| EPS Diluted | -5.71 | -3.82 | -4.32 | -2.77 | -3.67 |
| Normalized Diluted EPS | -1.39 | -2.39 | -2.70 | -1.73 | -2.30 |
| Average Basic Shares Outstanding | 17.90M | 8.67M | 8.62M | 8.47M | 8.39M |
| Average Diluted Shares Outstanding | 17.90M | 8.67M | 8.62M | 8.47M | 8.39M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |